In Heon Lee

Dr. In Heon Lee

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 March 2020 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
PCPeiming Chen
Peiming Chen
XZXiaoping Zhang
Xiaoping Zhang
AVAlessandro Venosa
Alessandro Venosa
ILIn Heon Lee
In Heon Lee
DMDaniel Myers
Daniel Myers
Patrick SinkoPatrick Sinko
Patrick Sinko
Persistent activation of macrophages (MP)s into a proinflammatory M1 or anti-inflammatory M2 phenotype plays a role in several pathological conditions, including autoimmune diseases, fibrosis, infections, atherosclerosis and tumor development. The mannose receptor (MR, CD206), expressed at low levels on resting MPs and absent on M1 MPs, is highly expressed on M2 MPs, making it a potential target and drug delivery portal. Recently, we developed a novel, highly selective MR targeting ligand (MRTL), consisting of two mannose molecules separated by a monodisperse 12 unit poly(ethylene glycol) linker, to enhance the cellular uptake of polymeric nanocarriers. The feasibility of using the MRTL ligand for selectively targeting M2 MPs for intracellular delivery of nanoparticles (NPs) was investigated. Rat peritoneal MPs were differentiated into an M1 or M2 phenotype using IFN-γ and IL-4/IL-13, respectively. Expression of the M1 marker, inducible nitric oxide synthase (iNOS), and the M2 markers arginase (Arg)-1 and MR (at both the mRNA and protein levels) confirmed MP phenotypic activation. Resting, M1 and M2 MPs were treated with fluorescein isothiocyanate (FITC)-labeled MRTL or NPs displaying FITC-labeled MRTL at two surface densities (1 and 10%) and examined by confocal microscopy. Intracellular fluorescence was also quantified. Uptake of the MRTL was 2.4- and 11.8-fold higher in M2 MPs when compared to resting or M1 MPs, respectively, consistent with marker expression levels. Mannan, a competitive inhibitor of the MR, abrogated MRTL uptake. MRTL also co-localized with a fluid-phase endocytosis marker, further suggesting that uptake was mediated by MR-mediated endocytosis. Intracellular NP fluorescence was confirmed by flow cytometry and by confocal microscopy. MRTL-NPs accumulated intracellularly with no significant cell surface binding, suggesting efficient translocation. NPs displaying a low surface density (1%) of the MRTL exhibited significantly higher (2.3-fold) uptake into M2 MPs, relative to resting and M1 MPs. The 10% MRTL-NPs displayed greater uptake by M2 MPs when compared to resting and M1 MPs, but less uptake than 1% MRTL-NPs into M2 MPs. Control FITC-labeled plain NPs did not exhibit selective MP uptake. These studies demonstrate that M2 MPs are selectively targeted by NPs displaying a novel bivalent ligand that utilizes the MR as a target/portal for cell entry. This study also establishes the feasibility of the approach allowing for further investigation in vivo.

1 May 2019 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Closed access
ILIn Heon Lee
In Heon Lee
MPMatthew S. Palombo
Matthew S. Palombo
XZXiaoping Zhang
Xiaoping Zhang
Zoltan SzekelyZoltan Szekely
Zoltan Szekely
Patrick SinkoPatrick Sinko
Patrick Sinko

27 March 2024 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
TRTomas L. Roldan
Tomas L. Roldan
SLShike Li
Shike Li
CGChristophe Guillon
Christophe Guillon
NHNed D. Heindel
Ned D. Heindel
JLJeffrey D. Laskin
Jeffrey D. Laskin
Patrick SinkoPatrick Sinko
Patrick Sinko
NDH-4338 is a highly lipophilic prodrug comprising indomethacin and an acetylcholinesterase inhibitor. A design of experiments approach was used to synthesize, characterize, and evaluate the wound healing efficacy of optimized NDH-4338 nanosuspensions against nitrogen mustard-induced skin injury. Nanosuspensions were prepared by sonoprecipitation in the presence of a Vitamin E TPGS aqueous stabilizer solution. Critical processing parameters and material attributes were optimized to reduce particle size and determine the effect on dissolution rate and burn healing efficacy. The antisolvent/solvent ratio (A/S), dose concentration (DC), and drug/stabilizer ratio (D/S) were the critical sonoprecipitation factors that control particle size. These factors were subjected to a Box–Behnken design and response surface analysis, and model quality was assessed. Maximize desirability and simulation experiment optimization approaches were used to determine nanosuspension parameters with the smallest size and the lowest defect rate within the 10–50 nm specification limits. Optimized and unoptimized nanosuspensions were prepared and characterized. An established depilatory double-disc mouse model was used to evaluate the healing of nitrogen mustard-induced dermal injuries. Optimized nanosuspensions (A/S = 6.2, DC = 2% w/v, D/S = 2.8) achieved a particle size of 31.46 nm with a narrow size range (PDI = 0.110) and a reduced defect rate (42.2 to 6.1%). The optimized nanosuspensions were stable and re-dispersible, and they showed a ~45% increase in cumulative drug release and significant edema reduction in mice. Optimized NDH-4338 nanosuspensions were smaller with more uniform sizes that led to improved physical stability, faster dissolution, and enhanced burn healing efficacy compared to unoptimized nanosuspensions.

17 April 2026 in Nicotine & Tobacco Research
Verified
Journal Article
Open access
JPJessica Pepper
Jessica Pepper
ILIn Heon Lee
In Heon Lee
AMAlexander Maki
Alexander Maki
TLTaylor Lee
Taylor Lee
JHJonathan Hannings
Jonathan Hannings
JBJennifer K Bernat
Jennifer K Bernat
Introduction: The synthetic cooling agent WS-3 (N-ethyl-p-menthane-3-carboxamide) elicits a cooling sensation without a minty taste. In areas with menthol cigarette sales prohibitions, such as California, tobacco companies have marketed cigarettes with WS-3 as alternatives to menthol cigarettes. We examined sales of cigarettes with WS-3 in NielsenIQ’s Retail Measurement Services Pacific division, which includes the state of California. Methods: With NielsenIQ data, we estimated sales of cigarettes with WS-3 from June 2022 to March 2024. We compared the NielsenIQ Pacific division, which includes California and two less populous states (Washington and Oregon), to all other divisions combined. Within the Pacific division, we compared trends in sales of cigarettes with WS-3 to menthol cigarettes. Results: In our study period, cigarettes with WS-3 appeared in the NielsenIQ Pacific division approximately 2 weeks before the implementation of California’s menthol cigarette prohibition in December 2022 and did not appear elsewhere in substantive quantities (>5 cartons) until Spring 2023. Most (87.0%) sales of cigarettes with WS-3 during the study period occurred in the Pacific division, peaking near 19 000 weekly carton sales. Weekly sales of Pacific division menthol cigarettes dropped by more than 100 000 cartons in 2 months after California’s prohibition. Conclusion: In the Pacific division, California’s menthol cigarette prohibition appears to have moderately reduced sales of menthol cigarettes and spurred sales of cigarettes with WS-3. Observationally, these sales data suggest that cigarettes with WS-3 only partially displaced the declining sales of menthol cigarettes. Future research could examine reasons for and experiences using cigarettes with WS-3. Implications: Tobacco companies explicitly marketed cigarettes with the synthetic cooling agent WS-3 as replacements for menthol cigarettes. Sales data from NielsenIQ’s Pacific division suggest that California’s menthol cigarette prohibition may have reduced sales of menthol cigarettes and spurred the introduction of cigarettes with WS-3 into the marketplace. The findings suggest that sales of cigarettes with WS-3 did not fully offset the decrease in menthol cigarette sales.